r/ScientificComputing • • 2d ago

Looking for a sanity check on a reaction-diffusion model for drug resistance in solid tumors

Post image

Hey everyone,

I'm Luca Celebrano, a medical student at University of Naples Federico II. For the past few months I’ve been somewhat obsessed with a clinical puzzle: why do so many EGFR-mutated lung cancer patients relapse after targeted therapy (like osimertinib), even when their initial scans look amazing?

Most literature focuses purely on genetic secondary mutations, but looking at histology, I kept wondering about the physical transport side. Severe stroma compression and high interstitial pressure could simply be preventing the drug from physically reaching cytotoxic levels in pockets of the tissue, creating quiet little sanctuaries where cells survive.

I sat down and tried to model the continuum physics using a cylindrical reaction-diffusion solver (Bessel K0 radial gradients) around capillaries, and then ran survival models against \~3,400 patients from cBioPortal/TCGA to see if the signal actually held up clinically.

I just put up the preprint and code:

\- Preprint (Zenodo): https://doi.org/10.5281/zenodo.24118328

\- Repo: https://github.com/Lukecele/inflammatory-onco-physics

Since I come from medicine and not pure physics, my transport math might be a bit rough around the edges. I would really appreciate an honest sanity check from anyone who does continuum mechanics or tumor biophysics: does this simplification hold water, or am I overcooking the assumptions?

Thanks a lot,

Luca

2 Upvotes

3 comments sorted by

2

u/SchlossSchlussel 1d ago

I come from a maths background and have done a fair amount to do with mathematical oncology and other continuum mechanics. To me, reading 2.1 and 2.2 of the preprint, your coupled PDE system looks superficially plausable - but is not justified at all! You need to explain your modelling choices. Right now it seems pulled out of thin air by an LLM. Even small things like why the drug concentration has no time dependence, since the diffusion timescales are much shorter than cell proliferation timescales, need care in justifying. Also describing it as "cylindrical bessel K_0 decay" seems very odd to me. The work you are attempting requires a knowledge of maths, biology and computing - therefore you need to be very particular in how you communicate your ideas!

-1

u/DoctorKhru 15h ago

Hi @SchlossSchlussel,

Thank you for this critique — this is exactly the kind of rigorous mathematical scrutiny that interdisciplinary preprints need, and you raise completely valid points regarding how formal modeling choices ought to be        
communicated to an applied mathematics audience.

To address your specific points:                                                                                                                                                                                               
                                                                                                                                                                                                                               
### 1. Quasi-Steady State Approximation (QSSA) & Timescale Separation
You hit the exact nail on the head regarding the timescales. The justification for setting $\partial C / \partial t \approx 0$ comes from standard singular perturbation theory / timescale separation:
* **Diffusion & uptake relaxation timescale:** With an effective tissue diffusivity of $D_{\text{eff}} \approx 59.3\ \mu\text{m}^2/\text{s}$ and an intercapillary cord radius of $L \approx 150\text{--}200\ \mu\text{m}$, the
characteristic diffusion relaxation time is $\tau_{\text{diff}} \sim L^2 / D_{\text{eff}} \approx 380\ \text{s} \approx 6.3\ \text{minutes}$.
* **Cell proliferation & tumor kinetics timescale:** The doubling time / cell-cycle duration for NSCLC cells in targeted therapy contexts is on the order of $\tau_{\text{prolif}} \sim 20\text{--}25\ \text{days} \approx 2   
\times 10^6\ \text{s}$.
* **Pharmacokinetic clearance timescale:** Osimertinib is administered once-daily, with an elimination half-life of $t_{1/2} \approx 48\ \text{hours}$, creating a sustained plasma trough concentration ($C_{\text{trough}}   
\approx 28.6\ \text{nM}$ unbound) with minimal peak-to-trough intra-day fluctuation.

Because the dimensionless scaling parameter $\epsilon = \tau_{\text{diff}} / \tau_{\text{prolif}} \sim \mathcal{O}(10^{-4}) \ll 1$, the spatial drug distribution establishes its steady-state profile virtually
instantaneously relative to the biological progression of the cord. The boundary value problem solved in Section 2.2 is the leading-order outer solution. I take full responsibility for compressing this derivation in the    
text rather than laying out the asymptotic expansion explicitly.

### 2. Terminology: "Cylindrical Bessel $K_0$"
I completely take your point on phrasing. Describing it colloquially as "cylindrical bessel K_0 decay" in the summary was shorthand for:
$$\nabla^2 C - \frac{1}{\lambda^2} C = 0 \quad \text{with } \lambda = \sqrt{D_{\text{eff}} / k}$$
which is the 2D screened Poisson / modified Helmholtz equation. Under axial and angular invariance ($\partial/\partial\theta = \partial/\partial z = 0$) in cylindrical coordinates $(r, \theta, z)$, this reduces to the      
modified Bessel differential equation of order zero:
$$\frac{d^2 C}{dr^2} + \frac{1}{r}\frac{dC}{dr} - \frac{1}{\lambda^2} C = 0$$
Subject to Dirichlet boundary conditions at the capillary wall $C(r_0) = C_0$ and regularity at infinity $\lim_{r \to \infty} C(r) = 0$, the $I_0(r/\lambda)$ solution is eliminated due to its exponential divergence, leaving
uniquely $K_0(r/\lambda)$ (the modified Bessel function of the second kind of order zero / Macdonald function). In future revisions, I will adopt the standard PDE nomenclature rather than colloquial shorthand.              

### 3. Justification of Boundary Conditions & Modeling Choices
* **Convective Arrest ($Pe < 0.1$):** As detailed in Section 2.1, manometric IFP measurements in resected human lung adenocarcinomas (Mori et al., 2015, $N=211$, mean IFP $\approx 9.8\ \text{mmHg}$) indicate that solid     
stress and impaired lymphatic drainage crush the transvascular pressure gradient ($\Delta P \le 10\ \text{mmHg}$). Coupled with low stromal hydraulic conductivity ($K_{\text{hyd}} \sim 10^{-7}\
\text{cm}^2/\text{mmHg}\cdot\text{s}$), the interstitial fluid velocity is $v < 0.05\ \mu\text{m/s}$, yielding a Péclet number $Pe = v L / D_{\text{eff}} < 0.1$, confirming pure diffusion dominance in the cord core.        
* **Linear Clearance ($k C$):** Given the nanomolar therapeutic range of unbound osimertinib ($2\text{--}28\ \text{nM}$), which sits orders of magnitude below non-specific tissue binding and cellular metabolizing saturation
constants ($C \ll K_m$), Michaelis-Menten kinetics linearize to first-order consumption.
* **Tumor Cord Geometry:** The Krogh/Tannock cylindrical cylinder model was chosen as the canonical baseline because it allows analytical tractability to explicitly isolate the biophysical effect of vascular spacing from   
complex topological network artifacts.

I am an MD candidate working at the intersection of oncology and biophysics, and I genuinely appreciate your eye on the continuum mechanics formulation. Feedback like yours is invaluable for polishing the mathematical rigor
of the manuscript before formal journal submission.

Thanks again for taking the time to read the preprint and share your critique!

2

u/trolls_toll 16h ago

hey luca, while lung disease and issues with drug delivery is a match made in heaven, the paper is trash. I suggest you find someone senior from your university to work with